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Imaging of Arterial Inﬂammation
Keeping Our Cool on a Hot Topic*Connie W. Tsao, MD,yz Ramachandran S. Vasan, MDzx
Boston and Framingham, MassachusettsDespite advances in treatment of cardiovascular
disease (CVD) over the past several decades, its
burden remains high (1). Appropriately, contempo-
rary investigations have focused on the identiﬁcation
of patients at greatest risk for CVD. Although the
central role of inﬂammation within the atheroscle-
rotic plaque in the pathogenesis of CVD events has
been recognized (2), serologic biomarkers such as
C-reactive protein have not necessarily improved
CVD risk prediction (3). Alternatively, noninvasive
imaging may provide direct characterization and
quantitation of inﬂammation within the atheroscle-
rotic plaque, suggesting a role for an imaging
biomarker to improve CVD risk prediction incre-
mentally over standard risk factors.See page 1250To this end, the investigation by Figueroa et al. (4)
in this issue of iJACC delivers great promise of
the power of positron emission tomography (PET)
to identify vascular inﬂammation. In this study
of patients referred for evaluation of suspected ma-
lignancy, the investigators examined the relationship
of the ﬂuorine-2-deoxy-D-glucose (FDG)-PET
signal, indicative of inﬂammation, in the ascending
aorta to the development of a CVD event on follow-
up. In a retrospective review of 513 patients who*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
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disclose.underwent FDG-PET imaging, 44 patients devel-
oped CVD, deﬁned as a composite of acute coronary
syndrome, revascularization, new-onset angina, pe-
ripheral arterial disease, heart failure, stroke, tran-
sient ischemic attack, or CVD death. The degree of
signal intensity was measured as the ratio of the mean
aortic to blood pool standardized FDG uptake
value, termed target-to-background ratio (TBR).
TBR was associated positively with incident CVD
even after adjustment for confounding clinical vari-
ables, including the coronary artery calciﬁcation
score, and was inversely related to the time to inci-
dent CVD. Furthermore, the investigators observed
that addition of TBR to models improved discrimi-
nation (the C statistic improved from 0.62  0.03
[for a model without TBR] to 0.66  0.03 upon
addition of TBR) as well as the net reclassiﬁcation
index (NRI) of subjects (improvement of 27.5% and
22.3% for 10% and 6% intermediate-risk cut points).
Thus, the investigators concluded that FDG-PET
identiﬁcation of arterial inﬂammation may be help-
ful to assist in risk stratiﬁcation of participants at risk
for CVD in the sample studied.
Atherosclerosis is characterized by slow progres-
sion with a long clinically latent stage. However,
because plaque rupture results in arterial occlusion,
leading to acute coronary syndrome or stroke (5),
identiﬁcation of active plaques before their rupture
offers opportunities for therapeutic intervention.
The “vulnerable plaque” is thought to consist of a
lipid-rich core and a thin ﬁbrous cap, with inﬂam-
matory cells including macrophages (6). Increasing
evidence implicates a strong relationship between
atherosclerotic inﬂammation and CVD events (2).
Computed tomography, cardiac magnetic resonance,
and vascular ultrasonography, including echocardi-
ography, are able to detect the presence, quantity,
and characteristics of atherosclerotic plaques. How-
ever, this armamentarium of noninvasive imaging
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1261modalities largely is unable to capture inﬂammatory
activity within the plaque other than in experimental
settings. Thus, the ability to detect the inﬂamma-
tory component of atherosclerosis is attractive for
gaining insight into the potential vulnerability of
plaques.
In the past decade, FDG-PET has emerged as a
noninvasive tool that provides this missing element
of functional atherosclerotic imaging in humans
(7,8), and now the present study extends its role into
the avenue of CVD risk prediction. A prior study
investigated FDG-PET uptake in multiple regions
along the length of the aorta and showed that
FDG-PET was a strong predictor of CVD events
in a model additionally including age, sex, arterial
calciﬁcation, and at least 1 other traditional CVD
risk factor (9). However, the limitations of that
study included the small number of incident CVD
events and limited statistical modeling. Both studies
quantiﬁed the intensity of the signal on FDG-PET
imaging by TBR. The current investigation extends
prior knowledge by broadening the spectrum of
CVD events evaluated, including transient ischemic
attacks, angina, peripheral arterial disease, heart
failure, and CVD death. Furthermore, the current
study investigated the addition of TBR to tradi-
tional CVD risk assessment and extended the
ﬁndings to cancer-free individuals. Moreover, the
investigators observed an inverse association of TBR
with the timing of CVD, with greater TBR asso-
ciated with earlier CVD during the follow-up
period. To the extent that TBR may identify
vulnerable plaques with higher levels of active
inﬂammation, the ﬁndings are provocative and
suggest the need for prospective investigation of this
imaging technique in larger multiethnic cohorts.
However, several caveats must be considered,
which rein in enthusiasm for the implementation of
FDG-PET for routine imaging of atherosclerotic
plaques at this time. As acknowledged by the in-
vestigators, a retrospective study based on review of
a clinical tertiary care hospital database and available
medical records is subject to errors and bias in
classiﬁcation of exposures, clinical characteristics
(disease spectrum bias), and outcomes. In addition,
although the present study accrued more CVD
events relative to prior studies, the 44 composite
events still constrain statistical power for adequate
assessment of the performance of FDG-PET in
prediction of CVD. This point is further emphasized
by consideration of only the hard events (21 cases
of acute coronary syndrome, 2 cases of ischemic
stroke, 4 cases of peripheral arterial disease, and
2 CVD deaths). Greater numbers of CVD eventswould allow differentiation of the ability of FDG-
PET to predict CVD risk in groups of subjects
with varied demographic characteristics (such as
young vs. old, men vs. women, low risk vs. higher
risk, etc.) and by CVD subtype (stroke vs. coronary
events). Furthermore, the patients in this investiga-
tion were all referred to a tertiary care medical center
for suspected malignancy, thus limiting the general-
izability of these ﬁndings. Another important
concern is for patient safety. Whereas FDG-PET is
appropriate for oncologic applications, it imparts
substantial exposure to ionizing radiation and has
been associated with risk of cancer (10). Further ad-
vances in imaging techniques and the limitations of
the ﬁeld of imaging may serve to decrease the radia-
tion exposure. Nevertheless, the risk-beneﬁt ratio
must be weighed carefully if we are to consider
extending this technique to standard imaging of
arterial inﬂammation in the future.
In addition to the previously described limita-
tions, consideration of the incremental value of
FDG-PET for CVD risk prediction in this study
should give us further pause. First, it must be kept in
mind that attenuation correction scans have lower
sensitivity for the detection of coronary artery
calciﬁcation. Thus, the improvement of TBR to a
model including coronary artery calciﬁcation as a
covariate must be interpreted with caution. Next, it
has been noted in large cohorts that the C statistic
for models with traditional risk factors to predict
CVD and coronary disease is 0.76 (11). In the
current study, the C statistic in the model with
conventional risk factors was only 0.62  0.03. An
improvement of the C statistic with any new
biomarker is more often observed when the baseline
model without the biomarker itself has a low C
statistic (as in the current study). Thus, we must
consider the improvement in model discrimination
in this investigation with this understanding. In the
context of a moderately high baseline C statistic
with standard risk factors, the addition of novel
biomarkers such as C-reactive protein and brain
natriuretic peptide often does not signiﬁcantly
improve risk discrimination (11). Figueroa et al. (4)
were not able to include blood C-reactive protein
concentrations or other serum inﬂammatory bio-
markers associated with CVD in models due to lack
of available data. Because well-validated serum
biomarkers are simpler blood tests that do not
expose a subject to the potential risks and costs of
FDG-PET, a pertinent question is whether there
would be added utility of FDG-PET imaging in
models that incorporate these additional serum
biomarkers. Finally, the NRI is derived from
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1262improved reclassiﬁcation of both those with CVD
and without events when the additional variable of
interest is included in the model. In this study, the
27.5% improvement in NRI at the 10% risk cutoff
point was to a greater extent driven by reclassiﬁca-
tion of those who did not experience a CVD event
(14.8%) than those who developed new-onset CVD
(12.7%). The identiﬁcation of patients who will
develop CVD (upgrading of risk reclassiﬁcation) is
critical because an intervention may alter their nat-
ural course toward morbidity or mortality. On the
other hand, downgrading of risk reclassiﬁcation of
those who will not develop CVD does not directly
offer potential for therapeutic beneﬁt. Thus, while
the NRI improved signiﬁcantly in this study in a
statistical sense, the derivation of beneﬁt from FDG-
PET is somewhat less compelling, considering all
the other limitations of this study and its potential
side effects and costs.
The outlined caveats should not detract from
what is an important, hypothesis-generating study
that highlights both the ability to capture functional
arterial imaging in humans and the association of
arterial inﬂammation with CVD events. Rather, inaddition to validation of these ﬁndings in larger,
prospective studies in the future, this investigation
opens the ﬁeld of noninvasive imaging and
biomarker research to approach further questions,
including opportunities for the use of FDG-PET to
evaluate imaging response to anti-inﬂammatory
treatment and the extent to which any changes on
serial imaging tests correlate with improvement in
clinical outcomes. Eventually, for FDG-PET to
become a routine test in the clinical care of at-risk
patients, it will have to meet several of the criteria
for informative CVD biomarkers proposed by ex-
perts (12), including evidence related to its impact
on patient management and outcomes and cost-
effectiveness. While we must continue to “keep
our cool” when surveying the evidence for imaging
of arterial inﬂammation, the present study may be
only the tip of the iceberg in a “hot” area of
promising investigation.
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